 Shares of Bluebird Bio Inc. BLUE, 3.32 soared 71.8 in premarket trading on Monday, days after a Food and Drug Administration advisory committee voted in favor of two of the companys experimental gene therapies. On Thursday, the committee voted 15-0 that the benefits of elivaldogene autotemcel as a treatment for children and teens with early cerebral adrenoleukodystrophy outweigh the risks. 